
    
      This trial is a single arm, non-randomized prospective trial. Following histotripsy treatment
      of liver tumor(s), subjects will undergo imaging â‰¤36 hours post-index procedure to determine
      technical success. Subjects will then be followed for 30 days. Data through the 30-day time
      point will be used for a Regulatory Submission to the FDA. Additionally, subjects will be
      followed for five (5) years post-index procedure, with evaluations at the 6-month and annual
      time points to estimate the efficacy and safety profile of the HistoSonics System.
    
  